Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis
Status:
Recruiting
Trial end date:
2026-06-01
Target enrollment:
Participant gender:
Summary
The goal of this study is to learn if tilpisertib fosmecarbil (formerly known as GS-5290) is
effective and safe in treating participants with moderate to severe ulcerative colitis. The
study will compare participants in different treatment groups treated with tilpisertib
fosmecarbil with participants treated with placebo.
The primary objective of this study is to demonstrate the efficacy of tilpisertib
fosmecarbil, compared to placebo control, in achieving Clinical Response at Week 12.